Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activ...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Zhou, Lang, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., Davids, Matthew S.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2018
主題:
Clinical Trials And Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922273/
https://ncbi.nlm.nih.gov/pubmed/29305552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-788133
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料